Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.5% - Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) fell 3.5% during trading on Wednesday . The company traded as low as $21.56 and last traded at $21.76. 80,122 shares were traded during trading, a decline of 77% from the average session volume of 349,583 shares. The stock had previously closed at $22.55.

Analyst Upgrades and Downgrades

A number of research firms have commented on BCAX. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $35.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set an "overweight" rating on the stock. TD Cowen began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a "buy" rating on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a "buy" rating and a $47.00 price objective on the stock.

Bicara Therapeutics Stock Down 10.0 %

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares in the company, valued at $16,156,566. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder James E. Flynn acquired 70,000 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the acquisition, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.